Antithrombotic efficacy and safety of dabigatran etexilate in senile patients with nonvalvular atrial fibrillation
ZHANG Wei
YAO Lu
ZHU Li-zhang
WU Yun-tao
TIAN Guo-xiang
XIA Chang-quan
WANG Xiao-bing
TANG Yan
Abstract：Objective To observe the antithrombotic efficacy and safety of dabigatran etexilate in senile patients with nonvalvular atrial fibrillation (NVAF). Methods The senile patients (aged≥80, n=10) with nonvalvular AF (never taking oral antithrombotic drugs) were chosen from Nov. 2013 to Apr. 2014, and given oral dabigatran etexilate (55 mg) twice a day. The relative coagulation indexes and drug safety were observed after 1 m and 3 m. Results After treatment for 1 m and 3 m, prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT) and R value in thrombelastogram (TEG) were prolonged gradually compared with those before treatment (P<0.05). International normalized ratio (INR), D-dimer, K value in TEG, Angle angle and MA value had no statistical difference after treatment (P>0.05). PT, APTT and TT had statistical difference after treatment for 3 m compare those after treatment for 1 m (P<0.05). In 10 patients, there was no one with artery thrombosis event, 3 (30.0%) with dyspeptic symptoms, and 1 (10.0%) with subcutaneous ecchymosis. There were no adverse events of bleeding and liver or kidney damage occurred. Conclusion Dabigatran etexilate in low dose is effective and safe for treating senile patients with nonvalvular AF. Because of small sample and short time in this study, bigger sample and longer observation time are needed to understand further the antithrombotic efficacy and safety of dabigatran etexilate in senile patients.
Keywords：Dabigatran etexilateAtrial fibrillationSenile
Publication Date：2014-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：3( 419-421 )